Tender Details

Country: USA
Summary: Plague Guard Antibodies
UST Ref No: 127664375
Deadline: 10 Oct 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: S-133813
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Los Alamos National Laboratory scientists have developed high-affinity human antibodies that can quickly detect and potentially treat deadly, antibiotic-resistant plague infections, helping protect against both natural outbreaks and bioterror threats. The Challenge: Plague, caused by the bacterium Yersinia pestis, remains a serious threat—not just as a rare but deadly natural infection, but also as a potential bioweapon. Modern medicine relies heavily on antibiotics, but these can fail if the bacteria become resistant, which is a growing global concern. Rapid, accurate detection is also difficult, and existing diagnostic tools can produce false results or aren't practical for field use. Problems Solved: Scientists at Los Alamos National Laboratory developed high-affinity antibodies that are specifically designed to detect a key component (the F1 antigen) found in the most dangerous strains of Y. pestis. These antibodies are: Extremely sensitive and specific, detecting even tiny amounts of the plague bacterium. Designed to target two different parts of the F1 antigen, minimizing the risk of false positives. Resilient when chemically modified, allowing them to be used in both fast diagnostic tests and innovative treatments, including options that may work even if traditional antibiotics fail. This innovation enables more accurate diagnosis and opens the door to new treatments for plague, even in the face of antibiotic resistance or biological warfare scenarios. Key Advantages: High Affinity and Specificity: The affinity-matured antibodies exhibit picomolar binding affinities to the F1 antigen of Yersinia pestis, each recognizing a distinct epitope on the antigen. This enhances diagnostic precision and reduces the likelihood of false positives. Dual Application (Therapeutic and Diagnostic): The antibodies can be conjugated to metal chelators for radioimmunotherapy, offering an alternative to traditional antibiotics, which is crucia...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Plague Guard Antibodies - USA Tender

The ENERGY, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Plague Guard Antibodies. This tender is published on USARFP under UST Ref No: 127664375 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-10-10.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.